CHMP recommends expanded Humira label for pediatric uveitis

EMA's CHMP recommended expanding the label of Humira adalimumab from AbbVie Inc. (NYSE:ABBV) to include chronic, non-infectious anterior uveitis in patients ages ≥2 who had an inadequate response or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

The human mAb against tumor necrosis factor (TNF) alpha is approved for the indication in adults in Europe. Humira is also approved for autoimmune indications, including Crohn’s disease (CD), rheumatoid arthritis (RA), axial spondyloarthritis, psoriatic arthritis, chronic plaque psoriasis, ulcerative colitis (UC) and juvenile idiopathic arthritis...